

Alan J Thomas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5586755/publications.pdf>

Version: 2024-02-01

172
papers

11,537
citations

44042

48
h-index

33869

99
g-index

181
all docs

181
docs citations

181
times ranked

11887
citing authors

#	ARTICLE	IF	CITATIONS
1	Predictors of loneliness during the Covid-19 pandemic in people with dementia and their carers in England: findings from the DETERMIND-C19 study. <i>Aging and Mental Health</i> , 2023, 27, 521-532.	1.5	7
2	Mild cognitive impairment with Lewy bodies: neuropsychiatric supportive symptoms and cognitive profile. <i>Psychological Medicine</i> , 2022, 52, 1147-1155.	2.7	26
3	Cholinergic white matter pathways in dementia with Lewy bodies and Alzheimer's disease. <i>Brain</i> , 2022, 145, 1773-1784.	3.7	28
4	Genetic evaluation of dementia with Lewy bodies implicates distinct disease subgroups. <i>Brain</i> , 2022, 145, 1757-1762.	3.7	17
5	Olfactory impairment in mild cognitive impairment with Lewy bodies and Alzheimer's disease. <i>International Psychogeriatrics</i> , 2022, 34, 585-592.	0.6	10
6	Differential levels of plasma biomarkers of neurodegeneration in Lewy body dementia, Alzheimer's disease, frontotemporal dementia and progressive supranuclear palsy. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 651-658.	0.9	64
7	Blood mRNA Expression in Alzheimer's Disease and Dementia With Lewy Bodies. <i>American Journal of Geriatric Psychiatry</i> , 2022, 30, 964-975.	0.6	9
8	Assessment of autonomic symptoms may assist with early identification of mild cognitive impairment with Lewy bodies. <i>International Journal of Geriatric Psychiatry</i> , 2022, 37, .	1.3	6
9	Blood pressure and heart rate responses to orthostatic challenge and Valsalva manoeuvre in mild cognitive impairment with Lewy bodies. <i>International Journal of Geriatric Psychiatry</i> , 2022, 37, .	1.3	4
10	Inflammation in dementia with Lewy bodies. <i>Neurobiology of Disease</i> , 2022, 168, 105698.	2.1	26
11	A Longitudinal Study of Plasma pTau181 in Mild Cognitive Impairment with Lewy Bodies and Alzheimer's Disease. <i>Movement Disorders</i> , 2022, 37, 1495-1504.	2.2	11
12	A cohort study of the impact of COVID-19 on the quality of life of people newly diagnosed with dementia and their family carers. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2022, 8, e12236.	1.8	8
13	The relationship between plasma biomarkers and amyloid PET in dementia with Lewy bodies. <i>Parkinsonism and Related Disorders</i> , 2022, 101, 111-116.	1.1	7
14	Uniformity of cardiac 123I-MIBG uptake on SPECT images in older adults with normal cognition and patients with dementia. <i>Journal of Nuclear Cardiology</i> , 2021, 28, 2151-2163.	1.4	7
15	Prospective predictors of decline <i>v.</i> stability in mild cognitive impairment with Lewy bodies or Alzheimer's disease. <i>Psychological Medicine</i> , 2021, 51, 2590-2598.	2.7	7
16	Cognitive Decline in Mild Cognitive Impairment With Lewy Bodies or Alzheimer Disease: A Prospective Cohort Study. <i>American Journal of Geriatric Psychiatry</i> , 2021, 29, 272-284.	0.6	15
17	Sarcopenia and frailty in individuals with dementia: A systematic review. <i>Archives of Gerontology and Geriatrics</i> , 2021, 92, 104268.	1.4	62
18	Mild cognitive impairment with Lewy bodies: blood perfusion with arterial spin labelling. <i>Journal of Neurology</i> , 2021, 268, 1284-1294.	1.8	11

#	ARTICLE	IF	CITATIONS
19	The revised Addenbrooke's Cognitive Examination can facilitate differentiation of dementia with Lewy bodies from Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2021, 36, 831-838.	1.3	3
20	Mild Cognitive Impairment: the Manchester consensus. <i>Age and Ageing</i> , 2021, 50, 72-80.	0.7	80
21	Genetic variants in glutamate-, A β , and tau-related pathways determine polygenic risk for Alzheimer's disease. <i>Neurobiology of Aging</i> , 2021, 101, 299.e13-299.e21.	1.5	7
22	Introduction of a Management Toolkit for Lewy Body Dementia: A Pilot Cluster-Randomized Trial. <i>Movement Disorders</i> , 2021, 36, 143-151.	2.2	5
23	Functional connectivity of the nucleus basalis of Meynert in Lewy body dementia and Alzheimer's disease. <i>International Psychogeriatrics</i> , 2021, 33, 89-94.	0.6	12
24	The Impact of Environment on Gait Assessment: Considerations from Real-World Gait Analysis in Dementia Subtypes. <i>Sensors</i> , 2021, 21, 813.	2.1	31
25	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. <i>Nature Genetics</i> , 2021, 53, 294-303.	9.4	198
26	Balance Impairments as Differential Markers of Dementia Disease Subtype. <i>Frontiers in Bioengineering and Biotechnology</i> , 2021, 9, 639337.	2.0	6
27	Concomitant neurodegenerative pathologies contribute to the transition from mild cognitive impairment to dementia. <i>Alzheimer's and Dementia</i> , 2021, 17, 1121-1133.	0.4	40
28	Progression to Dementia in Mild Cognitive Impairment With Lewy Bodies or Alzheimer Disease. <i>Neurology</i> , 2021, 96, e2685-e2693.	1.5	15
29	Functional connectivity in mild cognitive impairment with Lewy bodies. <i>Journal of Neurology</i> , 2021, 268, 4707-4720.	1.8	10
30	Gene Expression Imputation Across Multiple Tissue Types Provides Insight Into the Genetic Architecture of Frontotemporal Dementia and Its Clinical Subtypes. <i>Biological Psychiatry</i> , 2021, 89, 825-835.	0.7	10
31	Utility of the pareidolia test in mild cognitive impairment with Lewy bodies and Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2021, 36, 1407-1414.	1.3	4
32	Accuracy of Cardiac Innervation Scintigraphy for Mild Cognitive Impairment With Lewy Bodies. <i>Neurology</i> , 2021, 96, e2801-e2811.	1.5	25
33	Hippocampal and insula volume in mild cognitive impairment with Lewy bodies. <i>Parkinsonism and Related Disorders</i> , 2021, 86, 27-33.	1.1	10
34	A meta-analysis of epigenome-wide association studies in Alzheimer's disease highlights novel differentially methylated loci across cortex. <i>Nature Communications</i> , 2021, 12, 3517.	5.8	72
35	Dementia with Lewy bodies: association of Alzheimer pathology with functional connectivity networks. <i>Brain</i> , 2021, 144, 3212-3225.	3.7	26
36	Genome-wide association findings from the brains for dementia research cohort. <i>Neurobiology of Aging</i> , 2021, 107, 159-167.	1.5	5

#	ARTICLE	IF	CITATIONS
37	Improving the diagnosis and management of Lewy body dementia: the DIAMOND-Lewy research programme including pilot cluster RCT. Programme Grants for Applied Research, 2021, 9, 1-120.	0.4	8
38	Progression of Clinical Features in Lewy Body Dementia Can Be Detected Over 6 Months. Neurology, 2021, 97, e1031-e1040.	1.5	11
39	Authors'™ response. British Journal of Psychiatry, 2021, 219, 523-524.	1.7	0
40	Slowing on quantitative EEG is associated with transition to dementia in mild cognitive impairment. International Psychogeriatrics, 2021, 33, 1321-1325.	0.6	7
41	In vivo nucleus basalis of Meynert degeneration in mild cognitive impairment with Lewy bodies. Neurolmage: Clinical, 2021, 30, 102604.	1.4	18
42	Accuracy of dopaminergic imaging as a biomarker for mild cognitive impairment with Lewy bodies. British Journal of Psychiatry, 2021, 218, 276-282.	1.7	18
43	Neuropsychological Impairments and Their Cognitive Architecture in Mild Cognitive Impairment (MCI) with Lewy Bodies and MCI-Alzheimer's™ Disease. Journal of the International Neuropsychological Society, 2021, , 1-11.	1.2	9
44	Neurodegenerative brain changes are associated with area deprivation in the United Kingdom: findings from the Brains for Dementia Research study. Acta Neuropathologica Communications, 2021, 9, 198.	2.4	4
45	Factors That Influence Habitual Activity in Mild Cognitive Impairment and Dementia. Gerontology, 2020, 66, 197-208.	1.4	16
46	New evidence on the management of Lewy body dementia. Lancet Neurology, The, 2020, 19, 157-169.	4.9	167
47	DETERMinants of quality of life, care and costs, and consequences of INequalities in people with Dementia and their carers (DETERMIND): A protocol paper. International Journal of Geriatric Psychiatry, 2020, 35, 290-301.	1.3	17
48	Differentiating dementia disease subtypes with gait analysis: feasibility of wearable sensors?. Gait and Posture, 2020, 76, 372-376.	0.6	68
49	Amyloid Imaging and Longitudinal Clinical Progression in Dementia With Lewy Bodies. American Journal of Geriatric Psychiatry, 2020, 28, 573-577.	0.6	14
50	The Neuropsychological Profile of Mild Cognitive Impairment in Lewy Body Dementias. Journal of the International Neuropsychological Society, 2020, 26, 210-225.	1.2	15
51	Early Disruption of Cortical Sleep-Related Oscillations in a Mouse Model of Dementia With Lewy Bodies (DLB) Expressing Human Mutant (A30P) Alpha-Synuclein. Frontiers in Neuroscience, 2020, 14, 579867.	1.4	9
52	The challenges of COVID-19 for people with dementia with Lewy bodies and family caregivers. International Journal of Geriatric Psychiatry, 2020, 35, 1431-1436.	1.3	20
53	Diffusion imaging in dementia with Lewy bodies: Associations with amyloid burden, atrophy, vascular factors and clinical features. Parkinsonism and Related Disorders, 2020, 78, 109-115.	1.1	10
54	Visuo-Perceptual and Decision-Making Contributions to Visual Hallucinations in Mild Cognitive Impairment in Lewy Body Disease: Insights from a Drift Diffusion Analysis. Brain Sciences, 2020, 10, 540.	1.1	4

#	ARTICLE	IF	CITATIONS
55	The Role of EEG in the Diagnosis, Prognosis and Clinical Correlations of Dementia with Lewy Bodiesâ€™A Systematic Review. <i>Diagnostics</i> , 2020, 10, 616.	1.3	24
56	Recalibrating the epigenetic clock: implications for assessing biological age in the human cortex. <i>Brain</i> , 2020, 143, 3763-3775.	3.7	100
57	Neuropsychiatric symptoms in limbic-predominant age-related TDP-43 encephalopathy and Alzheimerâ€™s disease. <i>Brain</i> , 2020, 143, 3842-3849.	3.7	17
58	Epigenetic regulation in the pathophysiology of Lewy body dementia. <i>Progress in Neurobiology</i> , 2020, 192, 101822.	2.8	10
59	Prospective longitudinal evaluation of cytokines in mild cognitive impairment due to <scp>AD</scp> and Lewy body disease. <i>International Journal of Geriatric Psychiatry</i> , 2020, 35, 1250-1259.	1.3	14
60	Clinical diagnosis of Lewy body dementia. <i>BJPsych Open</i> , 2020, 6, e61.	0.3	33
61	Quantitative EEG as a biomarker in mild cognitive impairment with Lewy bodies. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 82.	3.0	41
62	Microbleeds in dementia with Lewy bodies. <i>Journal of Neurology</i> , 2020, 267, 1491-1498.	1.8	8
63	Visual hallucinations in neurological and ophthalmological disease: pathophysiology and management. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 512-519.	0.9	75
64	EEG alpha reactivity and cholinergic system integrity in Lewy body dementia and Alzheimerâ€™s disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 46.	3.0	41
65	Research criteria for the diagnosis of prodromal dementia with Lewy bodies. <i>Neurology</i> , 2020, 94, 743-755.	1.5	365
66	Fluctuating cognition in the Lewy body dementias. <i>Brain</i> , 2019, 142, 3338-3350.	3.7	27
67	Neuropathological Changes in Dementia With Lewy Bodies and the Cingulate Island Sign. <i>Journal of Neuropathology and Experimental Neurology</i> , 2019, 78, 717-724.	0.9	15
68	Response to Dr. Kameyamaâ€™s letter to the editor. <i>Annals of Nuclear Medicine</i> , 2019, 33, 785-785.	1.2	0
69	Dynamic functional connectivity changes in Lewy body disease. <i>Brain</i> , 2019, 142, e68-e68.	3.7	3
70	Do Alzheimer's and Lewy body disease have discrete pathological signatures of gait?. <i>Alzheimer's and Dementia</i> , 2019, 15, 1367-1377.	0.4	40
71	Dementia with Lewy bodies: an update and outlook. <i>Molecular Neurodegeneration</i> , 2019, 14, 5.	4.4	203
72	Imaging in prodromal dementia with Lewy bodies: Where do we stand?. <i>International Journal of Geriatric Psychiatry</i> , 2019, 34, 635-646.	1.3	10

#	ARTICLE	IF	CITATIONS
73	123I-MIBG scintigraphy utility and cut-off value in a clinically representative dementia cohort. <i>Parkinsonism and Related Disorders</i> , 2019, 62, 79-84.	1.1	22
74	Inflammation in mild cognitive impairment due to Parkinson's disease, Lewy body disease, and Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2019, 34, 1244-1250.	1.3	31
75	Structural correlates of attention dysfunction in Lewy body dementia and Alzheimer's disease: an ex-Gaussian analysis. <i>Journal of Neurology</i> , 2019, 266, 1716-1726.	1.8	14
76	Prevalence and severity of symptoms suggestive of gastroparesis in prodromal dementia with Lewy bodies. <i>International Journal of Geriatric Psychiatry</i> , 2019, 34, 990-998.	1.3	3
77	Deep and Frequent Phenotyping study protocol: an observational study in prodromal Alzheimer's disease. <i>BMJ Open</i> , 2019, 9, e024498.	0.8	18
78	123I-FP-CIT striatal binding ratios do not decrease significantly with age in older adults. <i>Annals of Nuclear Medicine</i> , 2019, 33, 434-443.	1.2	8
79	Peripheral inflammation in mild cognitive impairment with possible and probable Lewy body disease and Alzheimer's disease. <i>International Psychogeriatrics</i> , 2019, 31, 551-560.	0.6	14
80	Dynamic functional connectivity changes in dementia with Lewy bodies and Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2019, 22, 101812.	1.4	88
81	Dysfunctional brain dynamics and their origin in Lewy body dementia. <i>Brain</i> , 2019, 142, 1767-1782.	3.7	94
82	Pathological Changes to the Subcortical Visual System and its Relationship to Visual Hallucinations in Dementia with Lewy Bodies. <i>Neuroscience Bulletin</i> , 2019, 35, 295-300.	1.5	15
83	A comparison of visual and semiquantitative analysis methods for planar cardiac 123I-MIBG scintigraphy in dementia with Lewy bodies. <i>Nuclear Medicine Communications</i> , 2019, 40, 734-743.	0.5	11
84	Beta amyloid deposition maps onto hippocampal and subiculum atrophy in dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2019, 73, 74-81.	1.5	16
85	Degeneration of dopaminergic circuitry influences depressive symptoms in Lewy body disorders. <i>Brain Pathology</i> , 2019, 29, 544-557.	2.1	33
86	Extravascular fibrinogen in the white matter of Alzheimer's disease and normal aged brains: implications for fibrinogen as a biomarker for Alzheimer's disease. <i>Brain Pathology</i> , 2019, 29, 414-424.	2.1	24
87	Diagnostic accuracy of dopaminergic imaging in prodromal dementia with Lewy bodies. <i>Psychological Medicine</i> , 2019, 49, 396-402.	2.7	51
88	Clinical and imaging correlates of amyloid deposition in dementia with Lewy bodies. <i>Movement Disorders</i> , 2018, 33, 1130-1138.	2.2	36
89	Molecular changes in the absence of severe pathology in the pulvinar in dementia with Lewy bodies. <i>Movement Disorders</i> , 2018, 33, 982-991.	2.2	24
90	Quantitative electroencephalography as a marker of cognitive fluctuations in dementia with Lewy bodies and an aid to differential diagnosis. <i>Clinical Neurophysiology</i> , 2018, 129, 1209-1220.	0.7	43

#	ARTICLE	IF	CITATIONS
91	Cortical tau pathology: a major player in fibre-specific white matter reductions in Alzheimer's disease?. Brain, 2018, 141, e44-e44.	3.7	4
92	Gait in Mild Alzheimer's Disease: Feasibility of Multi-Center Measurement in the Clinic and Home with Body-Worn Sensors: A Pilot Study. Journal of Alzheimer's Disease, 2018, 63, 331-341.	1.2	42
93	Neuropsychiatric symptoms and cognitive profile in mild cognitive impairment with Lewy bodies. Psychological Medicine, 2018, 48, 2384-2390.	2.7	66
94	Peripheral inflammation in prodromal Alzheimer's and Lewy body dementias. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 339-345.	0.9	141
95	Clinical prevalence of Lewy body dementia. Alzheimer's Research and Therapy, 2018, 10, 19.	3.0	135
96	Improving the identification of dementia with Lewy bodies in the context of an Alzheimer's-type dementia. Alzheimer's Research and Therapy, 2018, 10, 27.	3.0	43
97	Electroencephalographic derived network differences in Lewy body dementia compared to Alzheimer's disease patients. Scientific Reports, 2018, 8, 4637.	1.6	44
98	Feasibility of a staff training and support programme to improve pain assessment and management in people with dementia living in care homes. International Journal of Geriatric Psychiatry, 2018, 33, 221-231.	1.3	17
99	BOLD activation of the ventromedial prefrontal cortex in patients with late life depression and comparison participants. International Psychogeriatrics, 2018, 30, 629-634.	0.6	6
100	Functional connectivity in dementia with Lewy bodies: A within- and between-network analysis. Human Brain Mapping, 2018, 39, 1118-1129.	1.9	55
101	Non-pharmacological interventions for Lewy body dementia: a systematic review. Psychological Medicine, 2018, 48, 1749-1758.	2.7	47
102	Structural Brain Correlates of Attention Dysfunction in Lewy Body Dementias and Alzheimer's Disease. Frontiers in Aging Neuroscience, 2018, 10, 347.	1.7	12
103	A new visual rating scale for loflupane imaging in Lewy body disease. NeuroImage: Clinical, 2018, 20, 823-829.	1.4	14
104	05: DELAYS IN DIAGNOSING LEWY BODY DEMENTIA. Alzheimer's and Dementia, 2018, 14, P1647.	0.4	0
105	A β ₄₂ /A β ₄₀ and A β ₄₂ /A β ₃₈ Ratios Are Associated with Measures of Gait Variability and Activities of Daily Living in Mild Alzheimer's Disease: A Pilot Study. Journal of Alzheimer's Disease, 2018, 65, 1377-1383.	1.2	23
106	Orthostatic hypotension in patients with late-life depression: Prevalence and validation of a new screening tool. International Journal of Geriatric Psychiatry, 2018, 33, 1397-1402.	1.3	4
107	Revision of assessment toolkits for improving the diagnosis of Lewy body dementia: The <sc>DIAMOND</sc> Lewy study. International Journal of Geriatric Psychiatry, 2018, 33, 1293-1304.	1.3	31
108	Translating progress in neuroimaging into clinical practice. International Psychogeriatrics, 2018, 30, 607-609.	0.6	0

#	ARTICLE	IF	CITATIONS
109	Specific patterns of neuronal loss in the pulvinar nucleus in dementia with lewy bodies. Movement Disorders, 2017, 32, 414-422.	2.2	32
110	Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology. Journal of Psychopharmacology, 2017, 31, 147-168.	2.0	198
111	Diagnosis and management of dementia with Lewy bodies. Neurology, 2017, 89, 88-100.	1.5	2,805
112	Symptoms associated with Lewy body disease in mild cognitive impairment. International Journal of Geriatric Psychiatry, 2017, 32, 1163-1171.	1.3	31
113	Divergent functional connectivity during attentional processing in Lewy body dementia and Alzheimer's disease. Cortex, 2017, 92, 8-18.	1.1	32
114	Quantitative neuropathology: an update on automated methodologies and implications for large scale cohorts. Journal of Neural Transmission, 2017, 124, 671-683.	1.4	21
115	Autopsy validation of ¹²³ I-FP-CIT dopaminergic neuroimaging for the diagnosis of DLB. Neurology, 2017, 88, 276-283.	1.5	118
116	Development of assessment toolkits for improving the diagnosis of the Lewy body dementias: feasibility study within the DIAMOND Lewy study. International Journal of Geriatric Psychiatry, 2017, 32, 1280-1304.	1.3	39
117	Systemic Inflammation in Lewy Body Diseases. Alzheimer Disease and Associated Disorders, 2017, 31, 346-356.	0.6	36
118	Author response: Autopsy validation of ¹²³ I-FP-CIT dopaminergic neuroimaging for the diagnosis of DLB. Neurology, 2017, 89, 751-751.	1.5	6
119	[O5â€“04â€“06]: VALIDATION BY NEUROPATHOLOGY OF FPâ€“CIT NEUROIMAGING IN DEMENTIA WITH LEWY BODIES. Alzheimer's and Dementia, 2017, 13, P1462.	0.4	1
120	Parietal white matter lesions in Alzheimerâ€™s disease are associated with cortical neurodegenerative pathology, but not with small vessel disease. Acta Neuropathologica, 2017, 134, 459-473.	3.9	180
121	TDPâ€“43 pathology in Alzheimer's disease, dementia with Lewy bodies and ageing. Brain Pathology, 2017, 27, 472-479.	2.1	170
122	PET Tau and Amyloid-Î² Burden in Mild Alzheimerâ€™s Disease: Divergent Relationship with Age, Cognition, and Cerebrospinal Fluid Biomarkers. Journal of Alzheimer's Disease, 2017, 60, 283-293.	1.2	67
123	Decreased Levels of VAMP2 and Monomeric Alpha-Synuclein Correlate with Duration of Dementia. Journal of Alzheimer's Disease, 2016, 50, 101-110.	1.2	24
124	Changes to the lateral geniculate nucleus in Alzheimer's disease but not dementia with Lewy bodies. Neuropathology and Applied Neurobiology, 2016, 42, 366-376.	1.8	22
125	The landscape of pain management in people with dementia living in care homes: a mixed methods study. International Journal of Geriatric Psychiatry, 2016, 31, 1354-1370.	1.3	26
126	Computational meta-analysis of statistical parametric maps in major depression. Human Brain Mapping, 2016, 37, 1393-1404.	1.9	158

#	ARTICLE	IF	CITATIONS
127	Support and information needs following a diagnosis of dementia with Lewy bodies. <i>International Psychogeriatrics</i> , 2016, 28, 495-501.	0.6	32
128	Analysis of primary visual cortex in dementia with Lewy bodies indicates GABAergic involvement associated with recurrent complex visual hallucinations. <i>Acta Neuropathologica Communications</i> , 2016, 4, 66.	2.4	58
129	Diagnosing dementia. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2016, 77, C22-C25.	0.2	1
130	The segregated connectome of late-life depression: a combined cortical thickness and structural covariance analysis. <i>Neurobiology of Aging</i> , 2016, 48, 212-221.	1.5	33
131	Neural correlates of attention–executive dysfunction in lewy body dementia and Alzheimer's disease. <i>Human Brain Mapping</i> , 2016, 37, 1254-1270.	1.9	49
132	Evolution of clinical features in possible DLB depending on FP-CIT SPECT result. <i>Neurology</i> , 2016, 87, 1045-1051.	1.5	14
133	Revisiting DLB Diagnosis. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2016, 29, 249-253.	1.2	92
134	A randomised controlled trial of calcium channel blockade (CCB) with Amlodipine For the treatment of subcortical ischaemic vascular dementia (AFFECT): study protocol. <i>Trials</i> , 2016, 17, 324.	0.7	6
135	Frontal white matter hyperintensities, clasmotodendrosis and gliovascular abnormalities in ageing and post-stroke dementia. <i>Brain</i> , 2016, 139, 242-258.	3.7	129
136	Cortical tau load is associated with white matter hyperintensities. <i>Acta Neuropathologica Communications</i> , 2015, 3, 60.	2.4	102
137	Lessons from a pilot and feasibility randomised trial in depression (Blood pressure Rapid Intensive) Tj ETQq1 1 0.784314 rgBT /Overlook 0.5 5	0.5	5
138	Cortical Thickness in Dementia with Lewy Bodies and Alzheimer's Disease: A Comparison of Prodromal and Dementia Stages. <i>PLoS ONE</i> , 2015, 10, e0127396.	1.1	86
139	Neuropathologically mixed Alzheimer–s and Lewy body disease: burden of pathological protein aggregates differs between clinical phenotypes. <i>Acta Neuropathologica</i> , 2015, 129, 729-748.	3.9	168
140	Pharmacological Management of Lewy Body Dementia: A Systematic Review and Meta-Analysis. <i>American Journal of Psychiatry</i> , 2015, 172, 731-742.	4.0	200
141	Clinicians' ability to diagnose dementia with Lewy bodies is not affected by β 2-amyloid load. <i>Neurology</i> , 2015, 84, 496-499.	1.5	44
142	Management of late-life depression: a major leap forward. <i>Lancet, The</i> , 2015, 386, 2374-2375.	6.3	7
143	Vascular dementia. <i>Lancet, The</i> , 2015, 386, 1698-1706.	6.3	757
144	Clinical usefulness of dopamine transporter SPECT imaging with ¹²³ I-FP-CIT in patients with possible dementia with Lewy bodies: Randomised study. <i>British Journal of Psychiatry</i> , 2015, 206, 145-152.	1.7	52

#	ARTICLE	IF	CITATIONS
145	Amyloid PET Imaging in Lewy Body Disorders. American Journal of Geriatric Psychiatry, 2015, 23, 23-37.	0.6	83
146	Neuropathology of Depression in Alzheimer's Disease: Current Knowledge and the Potential for New Treatments. Journal of Alzheimer's Disease, 2015, 44, 27-41.	1.2	47
147	The Dementia Cognitive Fluctuation Scale, a New Psychometric Test for Clinicians to Identify Cognitive Fluctuations in People with Dementia. American Journal of Geriatric Psychiatry, 2014, 22, 926-935.	0.6	57
148	Visual complaints and visual hallucinations in Parkinson's disease. Parkinsonism and Related Disorders, 2014, 20, 318-322.	1.1	73
149	Mild cognitive impairment: Safe to drive?. Maturitas, 2014, 78, 82-85.	1.0	17
150	Examining carer stress in dementia: the role of subtype diagnosis and neuropsychiatric symptoms. International Journal of Geriatric Psychiatry, 2013, 28, 135-141.	1.3	84
151	A systematic review comparing clinical features in early age at onset and late age at onset late-life depression. Journal of Affective Disorders, 2013, 150, 161-170.	2.0	58
152	Late-life Mood Disorders. Edited by H. Lavretsky, M. Sajatovic, C. F. Reynolds III. (Pp. 770; £95.00; ISBN) Tj ETQq0 0.0 rgBT /Qverlock 10	2.7	0
153	Is depression really different in older people?. International Psychogeriatrics, 2013, 25, 1739-1742.	0.6	3
154	Relationship Between Cognition, Magnetic Resonance White Matter Hyperintensities, and Cardiovascular Autonomic Changes in Late-Life Depression. American Journal of Geriatric Psychiatry, 2012, 20, 691-699.	0.6	43
155	Morphometric Analysis of Neuronal and Glial Cell Pathology in the Caudate Nucleus in Late-Life Depression. American Journal of Geriatric Psychiatry, 2011, 19, 132-141.	0.6	36
156	Depression in Older People with Diabetes. , 2011, , 39-53.		0
157	A morphometric examination of neuronal and glial cell pathology in the orbitofrontal cortex in late-life depression. International Psychogeriatrics, 2011, 23, 132-140.	0.6	45
158	A study of orthostatic hypotension, heart rate variability and baroreflex sensitivity in late-life depression. Journal of Affective Disorders, 2011, 131, 374-378.	2.0	40
159	Relationship of orthostatic blood pressure to white matter hyperintensities and subcortical volumes in late-life depression. British Journal of Psychiatry, 2011, 199, 404-410.	1.7	44
160	White matter hyperintensities, cortisol levels, brain atrophy and continuing cognitive deficits in late-life depression. British Journal of Psychiatry, 2010, 196, 143-149.	1.7	113
161	Morphometric changes in early- and late-life major depressive disorder: evidence from postmortem studies. International Psychogeriatrics, 2009, 21, 844.	0.6	42
162	Soluble cell adhesion molecules in late-life depression. International Psychogeriatrics, 2007, 19, 914-920.	0.6	19

#	ARTICLE	IF	CITATIONS
163	Cholinesterase inhibitors in advanced Dementia with Lewy bodies: increase or stop?. International Journal of Geriatric Psychiatry, 2006, 21, 719-721.	1.3	15
164	Increase in Interleukin-1 β in Late-Life Depression. American Journal of Psychiatry, 2005, 162, 175-177.	4.0	269
165	Depression and vascular disease: what is the relationship?. Journal of Affective Disorders, 2004, 79, 81-95.	2.0	232
166	Elevation of cell adhesion molecule immunoreactivity in the anterior cingulate cortex in bipolar disorder. Biological Psychiatry, 2004, 55, 652-655.	0.7	50
167	A neuropathological study of periventricular white matter hyperintensities in major depression. Journal of Affective Disorders, 2003, 76, 49-54.	2.0	80
168	Neuropathological evidence for ischemia in the white matter of the dorsolateral prefrontal cortex in late-life depression. International Journal of Geriatric Psychiatry, 2003, 18, 7-13.	1.3	115
169	What happens when donepezil is suddenly withdrawn? An open label trial in dementia with Lewy bodies and Parkinson's disease with dementia. International Journal of Geriatric Psychiatry, 2003, 18, 988-993.	1.3	129
170	Ischemic Basis for Deep White Matter Hyperintensities in Major Depression. Archives of General Psychiatry, 2002, 59, 785.	13.8	350
171	Pathologies and Pathological Mechanisms for White Matter Hyperintensities in Depression. Annals of the New York Academy of Sciences, 2002, 977, 333-339.	1.8	119
172	Can early phase cardiac [123I]mIBG images be used to diagnose Lewy body disease?. Nuclear Medicine Communications, 0, Publish Ahead of Print, .	0.5	0